By Fineline Cube CanSino Biologics (HKG: 6185) announced on August 25, 2026 the signing of a strategic cooperation framework agreement with DeepGeneAI (Hangzhou) Biotechnology Co., Ltd. for the co‑development of mRNA personalized therapeutic cancer vaccines. The two parties will leverage their respective strengths in mRNA vaccine technology and AI‑driven tumor neoantigen discovery and design to jointly advance the R&D and commercialization of mRNA personalized therapeutic cancer vaccines.
Deal Milestone
| Item | Detail |
|---|---|
| Party A | CanSino Biologics (HKG: 6185) |
| Party B | DeepGeneAI (Hangzhou) Biotechnology Co., Ltd. |
| Agreement Type | Strategic cooperation framework agreement |
| Objective | Co‑development of mRNA personalized therapeutic cancer vaccines |
| Target Market | Global |
| Therapeutic Focus | Gastrointestinal solid tumors and rare tumors |
| Value Chain Coverage | Early‑stage R&D → clinical translation → regulatory filing → commercialization |
| Announcement Date | 25 Aug 2026 |
Division of Capabilities
| Partner | Role & Technological Assets |
|---|---|
| CanSino Biologics | Technical support leveraging its mRNA vaccine delivery, formulation, and R&D manufacturing capabilities |
| DeepGeneAI | AI‑driven neoantigen discovery and design platform — undertaking neoantigen prediction, screening, and sequence design optimization, and advancing related preclinical and clinical research |
Program Profile
- Modality: Personalized therapeutic cancer vaccines — mRNA‑based immunotherapies tailored to each patient’s tumor neoantigen profile
- Indication Priorities: Gastrointestinal solid tumors (a high‑incidence, high‑mortality cancer category) and rare tumors (underserved by conventional oncology pipelines)
- End‑to‑End Scope: The collaboration spans the entire value chain, from early‑stage R&D and clinical translation through regulatory filing to commercialization — a full‑cycle partnership structure rather than a single‑stage licensing deal
Market Impact & Outlook
- Personalized Oncology Vaccine Race: mRNA therapeutic cancer vaccines are among the most closely watched frontiers in oncology, with individualized neoantigen selection as the critical determinant of efficacy. DeepGeneAI’s AI prediction and design platform targets precisely this bottleneck.
- CanSino’s mRNA Pivot: Known for its viral‑vectored vaccine franchise, CanSino Biologics (HKG: 6185) extends its mRNA delivery, formulation, and manufacturing stack into therapeutic oncology — diversifying beyond prophylactic vaccines.
- GI and Rare Tumor Focus: Gastrointestinal cancers (gastric, colorectal, pancreatic, esophageal) carry heavy global incidence and mortality burdens; rare tumors face limited treatment options — both segments offer high unmet need and potential regulatory incentives.
- Global Ambition: With worldwide market targeting and full value‑chain coverage, the partnership positions the co‑developed vaccines for international regulatory filings and commercialization, not merely the China market.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding co‑development programs, clinical translation, regulatory filings, and commercialization of mRNA personalized therapeutic cancer vaccines. Actual results may differ due to risks including research feasibility, clinical trial outcomes, manufacturing scale‑up, regulatory timelines, and competitive dynamics.-Fineline Info & Tech